CC
GBT

Casdin Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Casdin Capital’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-50,000
Closed -$2.26M – 39
2018
Q2 		$2.26M Buy
+50,000
New +$2.28M 0.32% 34

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Casdin Capital's GBT Position: Q3 2022 in Review

Casdin Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 800,000 shares — an estimated $25.6M sold.

Casdin Capital first reported a position in GBT in Q4 2015 and held it in 27 quarters. The position peaked at $49M in Q3 2021. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Casdin Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Casdin Capital sold 800,000 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $25.6M.
  • Casdin Capital first reported a position in Global Blood Therapeutics, Inc. in Q4 2015 and held it in 27 quarters.
  • Casdin Capital's Global Blood Therapeutics, Inc. position peaked at $49M in Q3 2021.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Casdin Capital's 13F filing for Q3 2022, filed 14 Nov 2022.